Biomarkers of Immune Checkpoint Inhibitor Response and Toxicity: Challenges and Opportunities

Overview

Journal Immunol Rev

Specialties Allergy & Immunology
General Surgery

Date 2023 Jul 20

PMID 37470280

Authors

Rachel S Goodman

Seungyeon Jung

Justin M Balko

Douglas B Johnson

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors have transformed cancer therapy, but their optimal use is still constrained by lack of response and toxicity. Biomarkers of response may facilitate drug development by allowing appropriate therapy selection and focusing clinical trial enrollment. However, aside from PD-L1 staining in a subset of tumors and rarely mismatch repair deficiency, no biomarkers are routinely used in the clinic. In addition, severe toxicities may cause severe morbidity, therapy discontinuation, and even death. Here, we review the state of the field with a focus on our research in therapeutic biomarkers and toxicities from immune checkpoint inhibitors.

Citing Articles

Prognostic value of inflammatory and nutritional indexes among patients with unresectable advanced gastric cancer receiving immune checkpoint inhibitors combined with chemotherapy-a retrospective study.

Zhu M, Zhang L, Lai W, Yang F, Zhou D, Xu R PeerJ. 2024; 12:e18659.

PMID: 39713151 PMC: 11660861. DOI: 10.7717/peerj.18659.

Targeting the MAtrix REgulating MOtif abolishes several hallmarks of cancer, triggering antitumor immunity.

Li C, Kaur A, Pavlidaki A, Spenle C, Rajnpreht I, Donnadieu E Proc Natl Acad Sci U S A. 2024; 121(42):e2404485121.

PMID: 39382998 PMC: 11494334. DOI: 10.1073/pnas.2404485121.

Immune checkpoint inhibitor infusion times and clinical outcomes in patients with melanoma.

Fletcher K, Rehman S, Irlmeier R, Ye F, Johnson D Oncologist. 2024; 30(1).

PMID: 39191524 PMC: 11783311. DOI: 10.1093/oncolo/oyae197.

Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes.

Li T, Sun S, Li Y, Zhang Y, Wei L Front Immunol. 2024; 15:1418580.

PMID: 39136027 PMC: 11317269. DOI: 10.3389/fimmu.2024.1418580.

Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update.

Fletcher K, Johnson D J Immunother Cancer. 2024; 12(7).

PMID: 38964785 PMC: 11227828. DOI: 10.1136/jitc-2023-008591.

References

Tarhini A, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield L . Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015; 3:39. PMC: 4570556. DOI: 10.1186/s40425-015-0081-1. View

Johnson D, Bordeaux J, Kim J, Vaupel C, Rimm D, Ho T . Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Clin Cancer Res. 2018; 24(21):5250-5260. PMC: 6214750. DOI: 10.1158/1078-0432.CCR-18-0309. View

Maekura T, Naito M, Tahara M, Ikegami N, Kimura Y, Sonobe S . Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer. In Vivo. 2017; 31(5):1035-1039. PMC: 5656848. DOI: 10.21873/invivo.11166. View

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C . Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017; 28(6):1368-1379. DOI: 10.1093/annonc/mdx108. View

Garrido F, Ruiz-Cabello F, Aptsiauri N . Rejection versus escape: the tumor MHC dilemma. Cancer Immunol Immunother. 2017; 66(2):259-271. PMC: 11028748. DOI: 10.1007/s00262-016-1947-x. View

Tawbi H, Schadendorf D, Lipson E, Ascierto P, Matamala L, Castillo Gutierrez E . Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022; 386(1):24-34. PMC: 9844513. DOI: 10.1056/NEJMoa2109970. View

Swetter S, Thompson J, Albertini M, Barker C, Baumgartner J, Boland G . NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw. 2021; 19(4):364-376. DOI: 10.6004/jnccn.2021.0018. View

Axelrod M, Johnson D, Balko J . Emerging biomarkers for cancer immunotherapy in melanoma. Semin Cancer Biol. 2017; 52(Pt 2):207-215. PMC: 5851807. DOI: 10.1016/j.semcancer.2017.09.004. View

Bos R, Sherman L . CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010; 70(21):8368-77. PMC: 2970736. DOI: 10.1158/0008-5472.CAN-10-1322. View

10.

Moslehi J, Salem J, Sosman J, Lebrun-Vignes B, Johnson D . Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018; 391(10124):933. PMC: 6668330. DOI: 10.1016/S0140-6736(18)30533-6. View

11.

Katz J, Muller A, Prendergast G . Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008; 222:206-21. DOI: 10.1111/j.1600-065X.2008.00610.x. View

12.

Kanz B, Pollack M, Johnpulle R, Puzanov I, Horn L, Morgans A . Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer. 2016; 4:60. PMC: 5067899. DOI: 10.1186/s40425-016-0166-5. View

13.

Kyi C, Hellmann M, Wolchok J, Chapman P, Postow M . Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014; 2:19. PMC: 4079190. DOI: 10.1186/2051-1426-2-19. View

14.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

15.

Garrido F, Cabrera T, Aptsiauri N . "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer. 2010; 127(2):249-56. DOI: 10.1002/ijc.25270. View

16.

Patrinely Jr J, Johnson R, Lawless A, Bhave P, Sawyers A, Dimitrova M . Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol. 2021; 7(5):744-748. PMC: 7995124. DOI: 10.1001/jamaoncol.2021.0051. View

17.

Algazi A, Tsai K, Shoushtari A, Munhoz R, Eroglu Z, Piulats J . Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016; 122(21):3344-3353. PMC: 5767160. DOI: 10.1002/cncr.30258. View

18.

Johnson D, Nebhan C, Moslehi J, Balko J . Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022; 19(4):254-267. PMC: 8790946. DOI: 10.1038/s41571-022-00600-w. View

19.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

20.

Valero C, Lee M, Hoen D, Zehir A, Berger M, Seshan V . Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. JAMA Oncol. 2021; 7(5):739-743. PMC: 7893543. DOI: 10.1001/jamaoncol.2020.7684. View